Positive News from ASH 2014 About PD-1 Inhibitors for Hodgkin’s Lymphoma

During the 2014 American Society of Hematology (ASH) annual meeting, Dr. Philippe Armand from Dana-Farber Cancer Institute joined Patient Power to share some encouraging treatment news. He gave an explanation of checkpoint inhibitors and the PD-1 pathway related to treatment of blood cancers. Dr. Armand also shared positive results of studies and treatment with monoclonal antibodies nivolumab (in clinical trials) and pembrolizumab (Keytruda®).

Get email alerts | http://www.patientpower.info/alerts

Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo